Taltz (ixekizumab) — Medica

Initial criteria

• age > 18 years
• objective signs of inflammation defined as elevated C-reactive protein above upper limit of normal OR sacroiliitis on MRI
• prescribed by or in consultation with a rheumatologist

Reauthorization criteria

• therapy established for at least 6 months
• EITHER beneficial clinical response from baseline by objective measure (e.g., ASDAS, ASQoL, BASDAI, BASFI, BAS-G, BASMI, DFI, HAQ-S, or serum markers such as CRP or ESR) OR improvement in at least one symptom (e.g., decreased pain or stiffness, or improved function/activities of daily living)

Approval duration

initial 6 months, reauthorization 1 year